CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 265 enrolled
Drug / intervention
Daptomycin +1 moredrug
Likely dose
Daptomycin 4mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00772447
NCT00772447Phase 3Completed
CompareCT.gov

A Phase 3, Multicentre, Randomised, Investigator-blinded, Parallel-groupStudy of the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared With That of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects With cSSSI

AstraZeneca·interventional·Posted Oct 15, 2008·Updated Mar 9, 2015

In Brief

A Phase 3 clinical trial evaluating Daptomycin and Vancomycin for Skin Diseases and Infectious. Completed, enrolled 265 participants across 13 sites.

Detailed Summary

The objectives of this study is to evaluate the Safety and Efficacy of Intravenous Daptomycin (Cubicin®)Compared with that of Comparator (Vancomycin or Vancomycin Followed by Semi-synthetic Penicillin-cloxacillin) in the Treatment of Chinese Subjects with Complicated Bacterial Skin and Skin Structure Infection due to Gram-Positive Pathogens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Diseases, Infectious
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 15, 2008
Enrollment StartSep 1, 2008
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.7 years ago

Interventions

Daptomycindrug

4mg/kg IV ; Q 24 hr (once every 24 hours)

Vancomycindrug

Vancomycin - 1g per 12 hrs, for 7-14 days Or switch to Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin: \- 1 g every 6 hours or 2 g every 8 hours